ITM-22
/ ITM Isotope Technologies Munich
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 20, 2024
Phase 1 Trial of ITM-22 in Patients with Prostate-Specific Membrane Antigen (PSMA)-positive Progressive Metastatic Castration Resistant Prostate Cancer
(ANZCTR)
- P1 | N=60 | Not yet recruiting | Sponsor: ITM Oncologics GmbH
Metastases • New P1 trial • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1